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What's already known about this topic? 
• Psoriasis significantly impacts quality of life (QoL) in patients. 
• Generic, skin-specific and disease-specific instruments are used in psoriasis 
interventional studies. 
• In psoriasis randomized controlled trials (RCTs), biologics are the most 
researched interventions that report QoL. 
 
What does this study add? 
• The most commonly used QoL instruments in psoriasis RCTs are the DLQI, 
SF-36 & EQ-5D. 
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• There is an increasing use of QoL instruments in RCTs in psoriasis. 
• Minimal clinically important difference of QoL measure scores is under-
reported 
• There is inconsistent reporting of QoL data and a need for guidelines when 
reporting. 
 
Keywords: Psoriasis, systematic review, quality of life, treatment, DLQI 
 
Manuscript word count: 2445 (excluding abstract) 
Manuscript table count: 1 
Manuscript figure count: 4 
 
ORCID Numbers: 
 
Faraz Ali: 0000-0002-4184-2023 
Andrea Cueva: 000-0002-6260-370X 
Jui Vyas: 0000-0003-2839-2651 
Sam Salek: 0000-0002-4612-5699 
Andrew Finlay: 0000-0003-2143-1646 
Vincent Piguet: 0000-0001-6079-4517 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Abstract 
 
Background 
Planners of interventional studies in psoriasis face the dilemma of selecting suitable 
quality of life (QoL) measures. Systematic reviews (SR) have the potential of 
identifying psychometrically sound measures in a given therapeutic area, whilst 
guiding the development of practice guidelines. 
 
Objectives 
The aim of this SR was to generate evidence of the use of QoL instruments in 
randomised controlled trials (RCTs) for interventions in psoriasis.  
 
Methods 
The methodology followed PRISMA guidelines. Six databases were searched with 
388 search terms. Abstracts of articles were reviewed independently by two 
assessors, a third adjudicator resolved any opinion differences. Risk of bias was 
assessed using the JADAD scale. 
 
Results 
Of 3646 screened publications, 99 articles (100 trials) met eligibility criteria for 
inclusion, describing research on 33,215 subjects. 33 trials tested topical therapy, 18 
systemic, 39 biologics, 9 phototherapy and 10 tested other interventions. 
The Dermatology Life Quality Index (DLQI) was the most commonly used QoL 
instrument (number of studies=83, 83%), followed by the Short Form-36 (SF-36) (31, 
31%), EuroQoL (EQ-5D) (15, 15%), Psoriasis Disability Index (PDI) (14,14%) and 
Skindex (5, 5%). There was widespread inconsistency in the way that QoL data was 
reported. Of the 100 trials identified, 37 reported Minimal Clinically Important 
Difference (MCID); 32 were for DLQI, 10 for SF-36 and six for EQ-5D. 
 
Conclusions 
QoL measurement is increasingly being reported in RCTs of psoriasis. Formal 
guidelines are needed for assessment and publishing of QoL data. Researchers 
should consider whether MCID information is available, and development of MCID 
data should be encouraged.  
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Introduction 
 
From the psoriasis patient’s perspective, quality of life (QoL) improvement is as 
important as improvement in clinical signs 1. Health-related QoL (HRQoL) 
instruments are increasingly used as outcome measures 2-5 in assessing 
interventions 6,7. Types of HRQoL instruments used include generic, speciality-
specific and disease-specific; specific tools are perceived as more relevant and thus 
preferred by patients 8.  
 
Previous reviews have examined the impact of psoriasis interventions on QoL 9-12. 
De Korte et al. 9 reviewed QoL data with clinical and demographic correlations. 
Kitchen et al. 13 carried out a systematic review (SR) of patient-reported outcome 
measures and evidence of their validation in psoriasis. These reviews underscored 
the value of QoL measurement in psoriasis. However we need to understand how 
QoL has been reported in previous trials; a comprehensive review is needed of the 
use of QoL instruments in randomized controlled trials (RCTs) for interventions in 
psoriasis.  
 
The aims of this SR were to identify RCTs of therapies in psoriasis that have 
assessed QoL and to evaluate patterns of utility and reporting of QoL data. This SR 
should reveal how QoL instruments have been used across therapeutic trials, 
including consideration of the minimal clinically important difference (MCID), 
frequency of measurement and sensitivity to change. The review may be useful for 
those who wish to understand the patterns of use in interventional trials for psoriasis. 
 
Materials and Methods 
 
Data sources 
 
We searched six computerized bibliographical databases up to November 2014:  
Cochrane Library CENTRAL, MEDLINE, MEDLINE In-Process & Other Non-Indexed 
Citations, EMBASE, WEB OF SCIENCE Core Collection, SCOPUS. The search was 
restricted to publications in English and was conducted using PRISMA guidelines 
(Prospero registration no: CRD42015009193).  
 
Keywords were formulated using Scottish Intercollegiate Guidelines Network (SIGN) 
and COCHRANE search filters for RCTs and SCHARR search filters for QoL. 
Keywords for psoriasis treatments were developed through a pilot search of other 
SRs on psoriasis treatments and of the British National Formulary. Search filters are 
given in the Supplementary Material. We ran supplementary searches and reviewed 
trial registers and grey literature. Reference lists of all included studies and of recent 
reviews were also assessed. Electronic publications in advance of print were also 
included. 
Selection criteria 
 
We included RCTs of any psoriasis treatment using at least one QoL instrument in 
adults (aged 18 and over) with psoriasis of either sex and of any ethnicity, including 
all psoriasis subtypes of psoriasis. Psoriatic arthritis trials were only included if a 
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skin-specific QoL instrument was used to differentiate QoL impairment for arthritis 
from that of psoriasis.  
 
Exclusion criteria 
 
The exclusion criteria for the systematic review were as follows; psoriatic arthritis 
studies where it was not possible to differentiate data on QoL impact of arthritis from 
QoL impact of psoriasis, studies which included any patient less than 18 years of 
age, and articles where the change in QoL values cannot be reliably calculated 
(including graphical representation). For consistency, QoL data only presented as 
sub-scales, where total scores are usually calculated, were excluded. Abstracts and 
posters where further data is not available upon contacting the author were also 
excluded.  
Outcome measures extracted 
Primary Outcome 
 
Data recorded included QoL instrument used and scores at baseline, treatment and 
follow-up endpoints and change in QoL attributed to treatment. For studies with an 
open label extension, the data was only extracted for the period of the study while it 
was randomised and controlled. For cross-over trials, the data was extracted prior to 
the crossover. 
Secondary Outcomes 
 
Psoriasis Area and Severity Index (PASI) score or any other psoriasis severity scale 
(PSS) used. 
Data extraction and synthesis 
 
Two reviewers (FA and AC) extracted data independently from all eligible published 
studies, discussed any disagreements and, if necessary involved a third reviewer 
(AA) for resolution. We adapted a form, which included the Cochrane Risk of Bias 
tool, for recording data 14 that included study design, details of administration, 
methodological quality and duration of treatment and follow-up. Article quality was 
quantitatively rated using the JADAD score 15.  
 
We recorded PASI or any other PSS and all QoL data including the baseline, 
treatment and follow-up endpoint scores and whether the studies detailed QoL 
percentage change, full scores, graphs or MCID. 
 
Results 
 
Of 3646 screened records, 99 articles met the inclusion criteria, describing 100 
RCTs and 33,215 patients (Fig. 1). Some trials were reported in more than one 
publication: all relevant references are given in Table 1. Sixty-three studies were 
placebo-controlled, 33 head-to-head trials and 36 tested a single drug in different 
dosage regimens or formulations (total >99 as studies fulfilled more than one 
criterion). Although JADAD scores 15 were not integral to the inclusion criteria, Table 
1 ranks interventions from low to high methodological quality. 
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Of the 100 trials that measured QoL, 33 tested topical, 18 systemic, 39 biologics, 9 
phototherapy, and 10 tested other interventions including educational treatments, 
diet, writing exercises, balneotherapy, auriculotherapy, relaxation therapies and 
interdisciplinary care (Table 1, Fig. 2 and Fig. 5). The number of studies reporting 
each topical intervention were: calcipotriol (13 trials), calcipotriol/bethametasone (7), 
clobetasol (4) and dithranol (4). Systemic medications trials included: methotrexate 
(7), ciclosporin (3) and voclosporin (2). Biologic trials included etanercept (14), 
ustekinumab (8), adalimumab (7), infliximab (6) and alefacept (4). Quality of life was 
evaluated in nine phototherapy trials. In the category of “other interventions” QoL 
was used most commonly in educational (3) and diet (3) studies.  
 
The mean JADAD score was 3.34 (range 1-5, Table 1). QoL was tested a range of 
2-6 times for topical, 2-25 times for systemic and 2-12 times for biologic 
interventions. Sixteen trials lasted >12 weeks, 49 from 12 to 24 weeks and 35 >24 
weeks. The subject number ranged from 20 16 to 2546 17 patients, with a mean male: 
female ratio of 1.7:1 per study arm. Mean PASI at baseline ranged from 1.7 to 33.1.  
The range of mean QoL scores at baseline were: Dermatology Life Quality Index 
(DLQI) 1.7-20.1 (Minimum-maximum for this measure = 0-30); Short Form 36 (SF-
36) physical component summary (PCS) 32.7-56.2 (0-100) and mental component 
summary (MCS) 35.7-52.4 (0-100); EuroQoL (EQ-5D) Component I 0.48-0.74 (0 to 
1), EuroQoL Component II 55.3-76.4 (0-100); and Psoriasis Disability Index (PDI) 
7.6-52.6 (0-90). 
Instruments used 
 
Thirteen instruments were used to measure QoL; some studies used more than one. 
Five generic instruments were used: the SF-36 18; EQ-5D 19; General Health 
Questionnaire (GHQ-12) 20,21; Quality of Life Index (QLI) 22; and Sickness Impact 
Profile (SIP) 23,24  In addition, four dermatology specific instruments, three specific to 
psoriasis and one for scalp dermatitis were used: DLQI 25; Skindex 26; Dermatology 
Quality of Life Scales (DQOLS) 27; Freiburg Life Quality Assessment (FLQA-d) 28; 
PDI 24; 12-Item Psoriasis Quality of Life Questionnaire (PQOL-12) 29; Psoriatic 
Arthritis Quality of Life measure (PsAQoL) 30; and SCALPDEX 31. Of these, the DLQI 
was the most commonly used QoL instrument (number of studies=83, 83%), 
followed by the SF-36 (31, 31%), EQ-5D (15, 15%), PDI (14, 14%) and Skindex (5, 
5%).  
 
Minimal Clinically Important Difference (MCID) and Statistical Reporting 
 
Of the 100 trials identified, 37 reported MCID; 32 were for DLQI, 10 for SF-36 and six 
for EQ-5D.  The DLQI MCID was considered to be a score change of five 32 but is 
now reported as four 33. Of the 83 RCTs that utilised the DLQI, 32 trials reported the 
MCID. Change in mean DLQI scores from baseline to treatment end ranged from -
14.4 34 to +3.0 35. Where DLQI score changes were reported, 115 of 142 ‘study 
arms’ met the 4-point MCID 33. Biologic interventions usually attained DLQI MCID: 
91.2% (83 of 91 study arms) met the 4-point MCID. The MCID was attained by 
77.8% (14 of 18) of topical, and 52.4% (11 of 21) of systemic treatment arms. One 
RCT of infliximab measuring QoL at 100 weeks 35 reported 3 points worsening of 
DLQI. However, this study ended prematurely and had a low JADAD score of only 2. 
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Another trial, with a high JADAD score of 5 36 demonstrated mean DLQI score 
increasing by 0.4 after folic acid was added to methotrexate. The MCID was not met 
for any study arm. 
The SF-36 MCID is a change of three in the total score 37. The SF-36 was used in 31 
trials and MCID reported in 10. The mean SF-36 change from baseline to treatment 
end ranged from PCS -7.4 35 to +10.138,39 MCS from -0.3 40 to +12.2 39. Where 
extracting change in SF-36 MCS scores was possible, 52.2% (24 of 46) ‘study arms’ 
met the 3-point MCID: 58.3% (21 of 36) of biologic interventions met this. For PCS 
scores, 50% (24 of 48) of ‘study arms’ met the MCID as did 60.5% (23 of 38) of 
biologic interventions. Only 25% (1 of 4) of systemic and no topical treatments met 
the MCID for both MCS and PCS domains. 
The EQ-5D was used in 15 trials, 6 reported the MCID which is 0.05 41,42. The PDI 
was used in 14 trials: the MCID is not known. Skindex was used in five RCTs; 
MCIDs for Skindex versions have not been published. 
 
Fig. 3 shows correlation between PASI and absolute DLQI (R2=0.494) and 
percentage (R2 =0.641) score changes, where available. In some cases the 
correlation was weak 43, possibly attributed to non-optimal endpoint measurement for 
QoL where maximum effect may be missed 44. Furthermore some interventions may 
have a psychological impact not captured by clinical parameters.  
 
Table 1 gives the studies included that documented full QoL data and statistical 
significance for intervention versus comparator. Significant changes were reached in 
52 trials for the DLQI, 19 for the SF-36, 5 for both the EQ-5D and PDI and 2 for the 
Skindex. Conversely there was no statistical improvement in 19 trials for the DLQI, 6 
for the SF-36, 3 for the EQ-5D, 6 for the PDI and 3 for Skindex. Twelve trials did not 
report statistical significance for the DLQI, 6 for the SF-36, 4 for the EQ-5D and 2 for 
the PDI.  
 
The first two studies identified, that fulfilled inclusion criteria, were published in 1998 
45,46.  Since then, reports of psoriasis interventions that fulfilled inclusion criteria have 
gradually increased over time: 1998-2004 = 12, 2005-2009 = 33, and 2010-2014 = 
55 (Fig. 4). 
 
Discussion 
 
QoL assessment is a frequent component in assessing psoriasis treatment efficacy 
47. This SR has identified therapeutic RCTs that demonstrated extractable QoL data, 
inevitably with heterogeneity in design, disease severity and QoL reporting. Many 
trials were excluded because of inconsistent reporting and analysis of QoL (Fig. 1) 
48. Baseline and end-of-treatment values were not always provided. Often QoL 
scores were presented as percentage or value changes without pre or post-
intervention scores. Mean values were most commonly reported, though median 
values are preferable with ordinal data 47. Standard deviation, p-values or confidence 
intervals were sometimes omitted and intention-to-treat (ITT) numbers were 
sometimes omitted from the QoL data set. This presented challenges for 
synthesizing data. 
The MCID is the minimal change in score that is considered of clinical relevance 49. 
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Of the 13 QoL instruments used, only the DLQI, SF-36 and EQ-5D have MCID 
values reported in the literature. Although interventions may result in statistically 
significant QoL improvement, this does not necessarily correlate with clinically 
important change. MCID values enhance the clinical meaningfulness of QoL scores, 
particularly if data is correlated with clinical efficacy. Thirty-seven trials reported 
consideration of MCID, with the DLQI and SF-36 being the most commonly used 
instruments with known MCID. The EQ-5D was the only other used instrument with 
known MCID: this data is not reported as numbers were so low.  
 
The MCID of QoL measures may be determined using several methodologies, and 
at least nine approaches have been reported50. These may be categorised into two 
main groups: anchor-based and distribution based approaches. Whereas the former 
incorporates patient perspective, the latter determines MCID using statistical 
significance. The anchor-based method is the most commonly used for determining 
the MCID, as used in the case of the DLQI33. 
Each methodology has its limitations, for example, anchor-based methods have 
often been criticised for unequal changes required for deterioration versus 
improvement of a condition51. Several factors may influence MCID scores, including 
patient baseline status, disease group and severity, treatment and patient 
demographics. Furthermore, it is important to note that MCID values may differ 
significantly within the same population depending on the methodology chosen52. 
Therefore interpreting MCID scores should be considered in the context of these 
limitations. 
 
More generic QoL instruments were used (n=5) than specialty (n=4) or condition 
specific questionnaires (n=3). The DLQI was the most commonly used instrument; 
possibly because of the simplicity of reporting a single summary score, the ease of 
completion in 2 minutes 53, its widespread use in national psoriasis guidelines 54 
amongst other reasons 55. The frequency of QoL measurement varied across studies 
depending on intervention type and trial duration. The UK guidelines, that 
recommend DLQI measurement at 10 to 16 weeks depending on the biologic, may 
not capture the best DLQI responses for biologic therapies 44.  
Several reviews have explored the effects of biologic treatment on QoL 10,11,56,57, 
Other SRs have explored QoL in psoriasis; the review by De Korte et al. 9 was not 
limited to RCTs and this provided difficulties in interpreting the dataset. This SR 
investigates the patterns of use of QoL instruments as well as the reporting of the 
outcomes. We employed strict entry criteria allowing for robust comparison across 
interventions per QoL instrument. We only included data from the double-blind 
controlled phases of each trial. Nevertheless, the lack of adequate guidelines on QoL 
data reporting still rendered data analysis problematic. 
Kitchen et al. 13 reviewed the ability of psoriasis-specific instruments to adequately 
capture domains relating to psoriasis: no existing psoriasis specific patient reported 
outcome (PRO) instrument has sufficient evidence on validity, reliability and 
sensitivity to change, but both DLQI 58 and Skindex demonstrated content validity. 
However, this SR demonstrates that several generic and disease/specialty-specific 
instruments were sensitive to change with positive QoL outcomes.  
The DLQI and SF-36 are the most frequently used instruments across psoriasis 
RCTs. A European S3 guidelines report on psoriasis systemic treatment 59 described 
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the DLQI as an ‘important’ variable in assessment of treatment efficacy. However the 
DLQI has limitations, including previous criticisms of its uni-dimensionality and low 
representation of emotional aspects 60.  There is diverse practice in monitoring 
therapeutic effect on QoL and questionnaire preference. We rejected 113 RCTs 
because of inextricable QoL data. The European Academy of Dermatology and 
Venereology Task Force provides recommendations for use of QoL measures 61. 
Currently there is great variation in the quality of reporting of QoL data 62,63, creating 
difficulties in cross-interventional meta-analyses. This SR emphasizes the need for 
guidelines concerning appropriate reporting of QoL data.  
This review has several limitations. Only English language literature was examined 
and only studies with extractable QoL data were included. There was too little 
comparative data from other QoL instruments to be included. Several studies were 
excluded due to inadequate QoL data reporting. Collating data across studies other 
than RCTs was not possible due to the wide variation in methodologies. Although an 
author (AYF) is joint DLQI copyright holder, bias was countered by two independent 
principal reviewers conducting data search, extraction and synthesis, with a third 
independent adjudicator reviewer. 
We recommend improvement of QoL reporting to include baseline, treatment and 
follow-up endpoint absolute median scores with interquartile range. Patient numbers 
should always be reported as well as whether intention to treat was implemented, as 
previously suggested 62,63. If a graphical representation of QoL is published, it should 
be accompanied by numerical data. Authors should not submit only percentage 
and/or graphical data to represent study outcomes as this data cannot be used in 
meta-analysis and systematic reviews. Journals should furthermore implement such 
criteria prior to accepting publications. The MCID and validated band descriptors 
where available should be used to interpret data as this holds greater clinical value 
than statistical significance alone. Researchers should consider the availability of 
MCID when choosing QoL instruments, and be encouraged to publish MCID 
information. Whilst there are numerous approaches for calculating MCID scores, 
there is a need for consensus on new or improved methodological approaches 
towards calculating MCID. Existing methodologies should be cautiously taken into 
account by clinicians and researchers alike to facilitate the interpretation of results. 
Though minimal change is clinically important, the question arises of whether 
intervention endpoints should target perfect quality of life, rather than demonstrating 
a measurable improvement. 
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Tables 
 
Table 1. Included studies: Jadad score, treatment duration, sample characteristics, QoL instruments and main psoriasis severity 
scale used 
Main QoL article, Year (salami 
publications used to derive non-
QoL data) 
J
A
D
A
D 
Interventions  
(Grouped per intervention, ranked by 
increasing JADAD score) 
Treat
ment 
End 
point 
(Wee
ks) 
Unles
s 
specif
ied 
Numb
er of 
Subje
cts 
 
QoL instruments used  
* Significant improvement 
vs comparator 
† No significant 
improvement vs 
comparator 
0 No significance data 
provided 
Psorias
is 
severity 
scale 
used 
(Primary
) 
 
BIOLOGICS 
 
Asahina 2010 64 3 Adalimumab vs Placebo 24 169 DLQI*, SF-36* PASI 
Genovese 2007 65 4 Adalimumab vs Placebo 12 100 DLQI*, HAQ-DI*, SF-36* 
(PCS ONLY), FACIT F† 
PGA 
Mease 2005 66 4 Adalimumab vs Placebo 24 313 DLQI*, HAQ-DI*,  
SF-36* (PCS ONLY) 
PASI 
Shikiar 2007 67(Gordon 2006 68, 
Menter 2010 69) 
4 Adalimumab vs Placebo 12 148 DLQI*, EQ-5D*,  
SF-36* (EXCEPT FOR PCS IN 40 
PASI 
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MG EOW ARM)  
Revicki 2007 70(Kimball 2011 71, 
Menter 2008 72, 73Revicki 2008 
73,) 
5 Adalimumab vs Placebo 16 1212 DLQI*, SF-36* PASI 
Revicki 2008 74(Saurat 2008 75, 
Navarini 2014 76, Saurat 2011 77) 
5 Adalimumab vs MTX 16 271 DLQI*, EQ-5D* PASI 
Thaci 2010 78, Paul 2012 79 5 Adalimumab + CAL/BD vs 
Adalimumab + Vehicle 
16 730 DLQI† PASI 
Lui 2012 80 2 Alefacept vs nUVB 16 98 DLQI† PASI 
Ellis 2003 81(Ellis 2001 82) 4 Alefacept vs Placebo 12 205 DLQI0, SF-360, DQOLS0 PASI 
Finlay 2003 83(Lebwohl 2003 84) 4 Alefacept vs Placebo 12 507 DLQI†, DQOLS* (15 MG ARM 
ONLY), SF-36* (PCS ONLY) 
PASI 
Yan 201185 4 Alefacept vs MTX 12 212 DLQI†, SF-36† PASI 
Papp 2014 86(Gordon 2012 87)  5 Briakinumab vs Placebo 12-40 2209 DLQI*, SF-36* PASI 
Gordon 2014 88(Papp 2012 89) 5 Brodalumab vs Placebo 12 198 DLQI*, 
SF-36* (140 MG ARM ONLY, AND 
MCS FOR 210 MG ARM) 
PASI 
Gladman 2014 90(Mease 2013 91) 3 Certolizumab vs Placebo 24 409 DLQI*, SF-36*, PSAQOL*,  
HAQ-DI* 
PASI 
Reich 2012 92 5 Certolizumab vs Placebo 12 176 DLQI0 PASI 
Dubertret 2006 38(Ortonne 2005 4 Efalizumab vs Placebo 12 793 DLQI*, SF-36* PASI 
 25 
39) 
Gordon 2003 3(Menter 2005 93) 5 Efalizumab vs Placebo 12 556 DLQI*, PSA* PASI 
Cassano 2006 94 1 Etanercept (Dose-comparison) 12 108 DLQI† PASI 
Dauden 2009 95(Ortonne 2008 96, 
Luger 2009 97) 
1 Etanercept (Continuous vs 
Intermittent) 
54 720 DLQI*, EQ-5D†, SF-36† PASI 
Gelfand 2008 17(Moore 2007 98) 2 Etanercept (Continuous vs 
Intermittent) 
24 2546 DLQI0, EQ-5D0 
(EuroQoL-FT), SF-360 
PASI 
Gniadecki 2012 99(Sterry 2010 
100) 
3 Etanercept (Dose-comparison) 12 752 DLQI*, EQ-5D†, HAQ-DI† PASI 
Lynde 2012 101 3 Etanercept vs Etanercept + nUVB 12 75 DLQI† PASI 
Ortonne 2013 102 3 Etanercept (Dose-comparison) 24 72 DLQI0 PASI 
Thaci 2014 5(Strohal 2013 103) 3 Etanercept (Dose-comparison) 12 273 DLQI* PASI 
Zachariae 2008 104 3 Etanercept + MTX (Tapered vs 
Continued) 
24 59 DLQI*, EQ-5D† PASI 
Krueger 2005 105(Papp 2005 106) 4 Etanercept vs Placebo 12 583 DLQI*, SF-36* PASI 
Feldman 2005 107(Leonardi 2003 
108) 
5 Etanercept vs Placebo 12 652 DLQI* PASI 
Gottlieb 2003 109 5 Etanercept vs Placebo 24 112 DLQI* PASI 
Reich 2009 110(Van de Kerkhof 
2008 111) 
5 Etanercept vs Placebo 12 142 DLQI*, SF-36* PASI 
Tyring 2007 112(Tyring 2006 113) 5 Etanercept vs Placebo 12 618 DLQI* PASI 
 26 
Reich 2013 35, extension of trial 
Barker 2011 114) 
2 Infliximab (Continuous vs 
Intermittent) 
100 441 DLQI0, SF-360 PASI 
Yang 2012 115 2 Infliximab vs Placebo 10 129 DLQI* PASI 
Barker 2011 114 3 Infliximab vs MTX 16 868 DLQI*, SF-36* (PCS ONLY),  
EQ-5D* 
PASI 
Feldman 2008 116(Menter 2007 
117) 
4 Infliximab vs Placebo 10 1430 DLQI*, SF-36* PASI 
Torii 2010 118 4 Infliximab vs Placebo 14 54 DLQI* PASI 
Bissonnette 2011 119 5 Infliximab vs Placebo 14 24 DLQI† m-
PPPASI 
Feldman 2005 120(Gottlieb 2004 
121) 
5 Infliximab vs Placebo 10 249 DLQI* PASI 
Reich 2006 122(Reich 2005123) 5 Infliximab vs Placebo 24 378 DLQI*, SF-36* PASI 
Krupashankar 2014 124 4 Itolizumab (Loading dose vs. Non-
loading dose) 
12 225 DLQI0, SF-360 PASI 
Leonardi 2012 125 5 Ixekizumab vs Placebo 8 142 DLQI* PASI 
Langley 2014 126 4 Secukinumab vs Etanercept vs 
Placebo 
12 2044 DLQI* (VS PLACEBO ONLY) PASI 
Mamolo 2014 127 4 Tofacitinib vs Placebo 12 197 DLQI*, SF-36* PASI 
Paul 2014 128(Reich 2014 129) 2 Ustekinumab + MTX (Gradual vs. 
Immediate withdrawal) 
16 489 DLQI0, EQ-5D0, VAS0 PASI 
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Nakagawa 2012 130(Igarashi 
2012 131) 
3 Ustekinumab vs Placebo 12 158 DLQI*, SF-36* (PCS ONLY), 
PDI* 
PASI 
Kimball 2012 132(Leonardi 2008 
133, Lebwohl 2010 134, Kimball 
2013 135) 
3 Ustekinumab vs Placebo 12 766 DLQI*, SF-360 PASI 
Zhu 2013 136 3 Ustekinumab vs Placebo 12 322 DLQI* PASI 
Langley 2010 137(Papp 2008 
138,139) 
4 Ustekinumab vs Placebo 12 1230 DLQI* PASI 
McInnes 2013 140 4 Ustekinumab vs Placebo 24 615 DLQI*, HAQ-DI*,  
SF-36* (EXCEPT MCS IN 45 MG 
ARM) 
PASI 
Kavanaugh 2010 141(Gottlieb 
2009 142) 
5 Ustekinumab vs Placebo 12 146 DLQI*, HAQ-DI* PASI 
Tsai 2012 143(Tsai 2011 144) 5 Ustekinumab vs Placebo 12 121 DLQI* PASI 
 
SYSTEMICS 
 
 Strand 2013 145(Papp 2012 146) 5 Apremilast vs Placebo 16 352 DLQI* (EXCEPT 10 MG ARM),  
SF 36* (MCS ONLY) 
PASI 
Möller 2010 147 4 Chondroitin Sulphate vs Placebo 12 116 DLQI†, SF-36† PASI 
Beissert 2009 148 3 Ciclosporin vs Mycophenolate 
Mofetil 
12 54 PDI† PASI 
 28 
Thaci 2002 149 4 Ciclosporin (Body-weight dependent 
dose vs Independent dose) 
12 212 PDI0 PASI 
Roberti 2014 43 4 Cytokines (low dose) 12 41 DLQI* PASI 
Bagel 1998 46 2 DAB389IL02 vs Placebo 4 70 DLQI0 PASI 
Greenberger 2012 150 3 Dunaliella bardawil (9-cis b-
carotene) vs Placebo 
12 44 DLQI* PASI 
Salim 2006 36 5 MTX + Folic acid vs MTX 12 22 DLQI† PASI 
Kaltwasser 2004 151(Nash 2006 
152) 
5 Leflunomide vs Placebo 24 190 DLQI*, HAQ* PASI 
Faurschou 2014 16 4 Liraglutide vs Placebo 8 20 DLQI† PASI 
Flytström 2008 153 3 MTX vs Ciclosporin 12 84 DLQI†, SF-36* (PCS ONLY) PASI 
Asawanonda 2006 154 4 MTX + nUVB vs MTX + Placebo 24 24 DLQI† PASI 
Ho 2010 155 2 Traditional Chinese Medicine vs 
MTX 
24 61 PDI* (FOR MTX VS PLACEBO) PASI 
Gupta 2008 156 3 Voclosporin vs Placebo 12 201 DLQI0, PDI0 PASI 
Kunynetz 2011 157(Papp 2008 
139) 
5 Voclosporin vs Placebo 12 451 DLQI* (FOR 0.3 AND 0.4 MG 
ARMS), PDI* (FOR 0.3 AND 0.4 
MG ARMS) 
PASI 
Drouin 2008 158 5 XP-828L (Dermylex) vs Placebo 8 26 DLQI* PASI 
 
PHOTOTHERAPY 
 
 29 
Koek 2009159 (Koek 2006160) 2 Home UVB (TL-01) vs Outpatient 
UVB (TL-01) 
’46 
irradi
ation
s’ 
 
196 
PDI†, SF-360, EQ-5D0 PASI 
Gahalaut 2014 161 2 PUVAsol + Isotretinoin vs PUVAsol 12 40 DLQI* PASI 
Klein 2011 162 2 Synchronous balneophototherapy vs 
nUVB monotherapy 
’35 
sessi
ons’ 
367 PDI†, SIP*,  
FLQA-d*(PHYSICAL 
COMPLAINTS AND GLOBAL 
HEALTH ONLY) 
PASI 
 
TOPICALS 
 
Choonhakarn 2010 163 4 Aloe Vera vs Triamcinolone 
Acetonide 
8 75 DLQI† PASI 
Ortonne 2014 164 5 Betamethasone valerate dressing vs 
CAL/BD ointment 
4 324 DLQI* TSS-4 
Wall 1998 45 1 CAL vs Dithranol 12 306 PDI†, SIP† IGA 
Ortonne 2009 165 (Kragballe 
2009166) 
2 CAL/BD scalp formulation vs CAL 
scalp solution 
8 312 SF-36†, Skindex-16* TSS 
Saraceno 2007 167 2 CAL/BD vs CAL 4 150 Skindex-29* PASI 
Zheng 2011 168 2 CAL/BD vs CAL 4 320 DLQI* VAS 
De Korte 2008 40(Van De Kerkhof 3 CAL vs Dithranol  12 106 Skindex-29†, SF-36† Modified 
 30 
2006 169) PASI 
Menter 2013 170 4 CAL/BD vs BD vs CAL vs Vehicle 8 1152 DLQI* (EXCEPT VS CAL 
GROUP) 
PASI 
Van De Kerkhof 2004 171 4 CAL/BD vs CAL vs Placebo 4 828 EQ-5D*, PDI† PASI 
Woo 2003 172 5 CAL + nUVB vs CAL vs Vehicle 20 
sessi
ons 
50 PDI† PASI 
Hutchinson 2000 173 1 Calcitriol vs Dithranol 8 114 PDI* PASI 
Bergstrom 2003 174 1 Clobetasol (Foam vs 
Cream/Solution) 
2 32 DLQI†, EQ-5D* PASI 
Menter 2009 4 1 Clobetasol propionate vs 
Calcipotriene + Betamethasone 
dipropionate 
4 93 PQOLS† ODS 
Mraz 2008 175 1 Clobetasol propionate (Spray vs 
Foam) 
2-4 77 DLQI* IGS 
Sofen 2011 176 2 Clobetasol propionate spray vs 
Vehicle 
4 81 Scalpdex* GSS 
Prins 2005 177 2 Dithranol (Short contact) + nUVB vs 
Dithranol (Inpatient) 
8-12 238 SIP*, PDI* PASI 
Alora-Palli 2010 178 2 Liquor Carbonis Distillate (LCD) 
Solution vs Calcipotriene cream 
12 60 DLQI† Modified 
PASI 
Bernstein 2006 179 2 M. Aquifolium vs Placebo 12 200 QLI* PASI 
 31 
Tiplica 2009 180 3 Mometasone furoate 0.1% + 
Salicylic acid 5% vs Mometasone 
furoate 0.1% 
1 359 DLQI0 PASI 
Galvez 2012 181 3 Sulphurous Mineral Waters Spray vs 
Distilled Water Spray 
2 39 DLQI† PASI 
 
OTHERS 
 
Lu 2012 182 2 Auricular therapy + Yinxieling 
formula vs Yinxieling formula 
8 84 DLQI† PASI 
Schmitt 2014 183 3 Interdisciplinary dermatological and 
psychiatric care for psoriasis vs 
Dermatological care for psoriasis 
24 47 DLQI† PASI 
Ersser 2012 184 2 Educational nursing intervention vs 
No education intervention 
6 64 DLQI† PASI 
Bostoen 2012 185  4 Educational programme vs No 
educational intervention 
12 29 DLQI*, PDI*, Skindex-
29† 
PASI 
Vedhara 2007 186 2 Emotional disclosure vs Standard 
control writing intervention 
0.5 59 DLQI0 PASI 
Guida 2014 34 2 Patients on immunosuppressives: 
Energy-restricted diet vs Usual diet 
24 44 DLQI* PASI 
Jensen 2013 187 2 Low energy diet vs Standard routine 
dietary guidance 
16 60 DLQI* PASI 
Fordham 2014 188 2 MCBT vs Usual treatment 8 29 DLQI* SAPASI 
 32 
 
 
 
 
 
 
 
 
 
 
 
MTX – Methotrexate 
nUVB – Narrowband UVB 
MCBT - Mindfulness-based cognitive therapy 
CALC – Calipotriol 
BD – Betamethasone diproprionate 
 
* Indicates significant improvement versus comparator(s) 
† Indicates no significant improvement versus comparator(s) 
0 Indicates no significance data was provided 
 
 
 
 
 
 
 
 
 
 
 
 
Chambers 2012 189 2 Online Healthcare Delivery vs In-
Office Care 
16 64 DLQI0, EQ-5D0 PASI 
Tabolli 2012 190 2 Writing exercise (Pennebaker) vs 
Educational intervention 
0.5 202 Skindex-29†, SF-36†, 
GHQ† 
PASI 
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Figure 1. Flow diagram of article selection 
 
 
 
 
 
 
 
 
Records identified through database 
searching 
- Medline (n=638) 
- Medline in Progress (n=54) 
- EMBASE (n=611) 
- Scopus (n=938) 
- Web of Science (n=1185) 
- Cochrane CENTRAL (n=167) 
(n=3593) 
 
Additional records identified through 
other sources 
- Trial registries (n=48) 
- Hand searching (n=5) 
(n=53) 
 
First screening (after duplicates removed) 
 (n=2016) 
 
Full-text articles assessed for eligibility 
 (n=329) 
 
Records excluded on basis of title and abstract 
 (n=1687) 
 
Full-text articles excluded with reasons 
 (n=230) 
 
Articles included in the systematic review  
 (n=99) 
 
Reasons for exclusion 
• No quality of life data (113) 
• Language other than English (4) 
• Not a randomised controlled trial (20) 
• Psoriatic Arthritis trials without skin-
relevant QoL data(14) 
• Salami publication of primary study (46) 
• No full articles available after contacting 
authors; these include conference 
abstracts, letters to editor, meeting 
posters, and trial protocols (15) 
• QoL data unable to be extracted (14) 
• Trials including subjects under the age of 
18 (4) 
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Figure 2. Number of randomised controlled trials of each intervention 
that measured HRQoL 
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Figure 3(a) 
 
  
 
Figure 3(b) 
 
 
Figure 3.  Correlation of (a) absolute change in DLQI scores with 
absolute change in PASI scores (R2 = 0.494) (b) percentage improvement 
in DLQI scores with percentage improvement in PASI scores (R2 = 0.641) 
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Figure 4. Increasing use of QoL instruments in included psoriasis 
studies since 1998 (n=100) 
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Example search strategy 
 
Medline OVID search strategy  
 
1.psoriasis.mp.orexpPsoriasis/ 
2.psoria*.mp. 
3.erythrodermicpsoriasis.mp. 
4.guttatepsoriasis.mp. 
5.pustularpsoriasis.mp. 
6.palmoplantarpsoriasis.mp. 
7.psoriasisvulgaris.mp. 
8.plaquepsoriasis.mp. 
9.localisedpustularpsoriasis.mp. 
10.localizedpustularpsoriasis.mp. 
11.inversepsoriasis.mp. 
12.scalppsoriasis.mp. 
13.nailpsoriasis.mp. 
14.inflammatorypsoriasis.mp. 
15.or/1-14 
16.intervention*.mp. 
17.treatment*.mp. 
18.topical.mp. 
19.systemic.mp. 
20.immunosuppressivedrug.mp. 
21.ImmunosuppressiveAgents/ 
22.NonprescriptionDrugs/ 
23.over-the-counter.mp. 
24.otc.mp. 
25.expTars/ 
26.(tarortars).tw. 
27.expSteroids/ 
28.expRetinoids/ 
29.retinoid*.tw. 
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30.steroid*.tw. 
31.expemollientagent/ 
32.emollient*.tw. 
33.expTacrolimus/ 
34.tacrolimus.tw. 
35.topicalimmunemodulator*.tw. 
36.(topicaladj3therap*).tw. 
37.(topicaladj3treatment*).tw. 
38.(topicaladj3agent*).tw. 
39.vitaminDanalogues.mp. 
40.calcipotriol.mp. 
41.dovonex.tw. 
42.dovobet.tw. 
43.xamiol.tw. 
44.calcipotriene.mp. 
45.taclonex.tw. 
46.Calcitriol/orcalcitriol.mp. 
47.silkis.tw. 
48.tacalcitol.mp. 
49.curatoderm.tw. 
50.vitaminD.tw. 
51.tars.mp.orTars/ 
52.(calamineandcoaltarointment).mp. 
53.coaltar.mp. 
54.calamine.mp. 
55.(coaltarandsalicylicacidointment).mp. 
56.coaltarpaste.mp. 
57.(zincandcoaltarpaste).mp. 
58.zincoxide.mp. 
59.alphosyl.mp. 
60.crudecoaltar.mp. 
61.dithranol.mp. 
62.anthralin.mp.orAnthralin/ 
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63.dithrocream.tw. 
64.micanol.tw. 
65.psorin.tw. 
66.zithranol.tw. 
67.topicalretinoids.mp. 
68.tazarotene.mp. 
69.zorac.tw. 
70.tazorac.tw. 
71.corticosteroid.mp. 
72.hydrocortisone.mp.orHydrocortisone/ 
73.dioderm.tw. 
74.mildison.tw. 
75.alphaderm.tw. 
76.calmuridHC.tw. 
77.eurax-hydrocortisone.tw. 
78.canestenHC.tw. 
79.daktacort.tw. 
80.fucidinH.tw. 
81.nystaform-HC.tw. 
82.timodine.tw. 
83.hydrocortisonebutyrate.mp. 
84.locoid.tw. 
85.locoidcrelo.tw. 
86.alclometasonedipropionate.mp. 
87.modrasone.tw. 
88.betamethasoneesters.mp. 
89.betamethasonevalerate.tw. 
90.betacap.tw. 
91.betesil.tw. 
92.betnovate.tw. 
93.betnovate-rd.tw. 
94.bettamousse.tw. 
95.diprosone.tw. 
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96.diprosalic.tw. 
97.betnovate-c.tw. 
98.betnovate-n.tw. 
99.fucibet.tw. 
100.lotriderm.tw. 
101.clobetasolpropionate.mp. 
102.clarelux.tw. 
103.dermovate.tw. 
104.etrivex.tw. 
105.dermovate-nn.tw. 
106.clobetasonebutyrate.mp. 
107.eumovate.tw. 
108.diflucortolonevalerate.mp. 
109.nerisone.tw. 
110.nerisoneforte.tw. 
111.fludroxycortide.mp. 
112.flurandrenolone.tw. 
113.haelan.tw. 
114.fluocinoloneacetonide.mp.orFluocinoloneAcetonide/ 
115.synalar1in4dilution.tw. 
116.synalar1in10dilution.tw. 
117.synalarc.tw. 
118.synalarn.tw. 
119.fluocinonide.mp.orFluocinonide/ 
120.metosyn.tw. 
121.fluocortolone.mp.orFluocortolone/ 
122.ultralanumplain.tw. 
123.fluticasonepropionate.mp. 
124.cutivate.tw. 
125.mometasonefuroate.mp. 
126.elocon.tw. 
127.triamcinoloneacetonide.mp.orTriamcinoloneAcetonide/ 
128.aureocort.tw. 
 41 
129.KeratolyticAgents/orkeratolytic.mp. 
130.salicylicacid.mp.orSalicylicAcid/ 
131.zinc.mp.andsalicylicacidpaste.tw. 
132.Sulfur/orsulphur.mp. 
133.expUltravioletRays/ 
134.expUltravioletTherapy/ 
135.ultraviolet*.tw. 
136.(uvorUVBorUVA).tw. 
137.phototherapy.mp.orPhototherapy/ 
138.ultravioletb.mp. 
139.UVB.mp. 
140.narrowbandUVB.mp. 
141.narrow-bandUVB.mp. 
142.narrowbandUVBtherapy.mp. 
143.broadbandlighttherapy.mp. 
144.ultravioletlight.mp. 
145.UVlight.mp. 
146.naturallight.mp. 
147.combinationlighttherapy.mp. 
148.photochemotherapy.mp.orPhotochemotherapy/ 
149.psoralen.mp. 
150.PUVA.mp. 
151.oralretinoids.mp. 
152.acitretin.mp.orAcitretin/ 
153.neotigason.tw. 
154.cyclosporin.mp.orCyclosporine/ 
155.ciclosporin.mp. 
156.deximune.tw. 
157.neoral.tw. 
158.sandimmune.tw. 
159.hydroxycarbamide.mp. 
160.hydrea.tw. 
161.hydroxyurea.mp.orHydroxyurea/ 
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162.methotrexate.mp.orMethotrexate/ 
163.metoject.tw. 
164.cytokinemodulators.mp. 
165.etanercept.mp. 
166.enbrel.tw. 
167.adalimumab.mp. 
168.humira.tw. 
169.infliximab.mp. 
170.remicade.tw. 
171.ustekinumab.mp. 
172.stelara.tw. 
173.efalizumab.mp. 
174.raptiva.tw. 
175.biologic*.mp. 
176.Psychotherapy/ 
177.(psycho*adj3therap*).tw. 
178.psychotherap*.tw. 
179.expCognitiveTherapy/ 
180.(cognit*adj3therap*).tw. 
181.((behaviourorbehavior)adj3therap*).tw. 
182.psychoeducation.tw. 
183.CBT.tw. 
184.expPeerGroup/ 
185.expSelf-HelpGroups/ 
186.(peeradj3group*).tw. 
187.((supportorself-helporselfhelp)adj3group*).tw. 
188.alternativetherapy.mp. 
189.homeopathy.mp.orHomeopathy/ 
190.Relaxation/orrelaxation.mp. 
191.oreganooil.mp. 
192.traditionaltreatment*.mp. 
193.oatextracts.mp. 
194.coldwaterfishoils.mp. 
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195.eveningprimroseoil.mp. 
196.teatreeoil.mp.or"TeaTreeOil"/ 
197.aloevera.mp.orAloe/ 
198.taichi.mp. 
199.yoga.mp.orYoga/ 
200.laser.mp. 
201.herbalmedication.mp. 
202.petroleumjelly.mp. 
203.massage*.mp. 
204.sharkcartilageextract.mp. 
205.meditation.mp.orMeditation/ 
206.complementarytherapy.mp.orComplementaryTherapies/ 
207.hypnotherapy.mp. 
208.milkthistle.mp.orMilkThistle/ 
209.expMotorActivity/ 
210.(physicaladj3activit$).tw. 
211.expExercise/ 
212.expExerciseTherapy/ 
213.exercis$.tw. 
214.expLifeStyle/ 
215.lifestyle$.tw. 
216.(lifeadj3style$).tw. 
217.expHealthBehavior/ 
218.(healthadj3(behavior$orbehaviour$)).tw. 
219.expDiet/ 
220.expDietarySupplements/ 
221.diet$.tw. 
222.nutrition$.tw. 
223.expObesity/ 
224.expBodyWeight/ 
225.obes$.tw. 
226.weight$.tw. 
227.expSmoking/ 
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228.(smokingorsmoker*).tw. 
229.expAlcohol-RelatedDisorders/ 
230.expAlcoholicBeverages/ 
231.alcohol*.tw. 
232.drinking.tw. 
233.expEmployment/ 
234.expOccupations/ 
235.(employment*oroccupation*orwork).tw. 
236.goeckermantherapy.mp. 
237.excimertherapy.mp. 
238.scalelifters.mp. 
239.non-biologicalmedications.mp. 
240.FishOils/orfishoil*.mp. 
241.vitamins.mp.orVitamins/ 
242.vitaminE.mp.orVitaminE/ 
243.VitaminA/orvitaminA.mp. 
244.mineral*.mp. 
245.selenium.mp.orSelenium/ 
246.Antimetabolites/orantimetabolite*.mp. 
247.thioguanine.mp.orThioguanine/ 
248.tioguanine.mp. 
249.miscellaneous.mp. 
250.immunomodulatoragents.mp. 
251.immunomodulatordrugs.mp. 
252.calcineurininhibitors.mp. 
253.anti-itch.mp. 
254.e45cream.mp. 
255.fumaricacidesters.mp. 
256.fumaricacidesters.mp. 
257.FAE.mp. 
258.sorbelene.mp. 
259.anti-fungal.mp. 
260.skinbiopsy.mp. 
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261.alefacept.mp. 
262.amevive.tw. 
263.or/16-262 
264.QOL.mp. 
265.qualityoflife.mp.or"QualityofLife"/ 
266.healthrelatedqualityoflife.mp. 
267.HRQOL.mp. 
268.EQ5D.mp. 
269.nationalpsoriasisfoundation.mp. 
270.skindex.mp. 
271.DLQI.mp. 
272.dermatologylifequalityindex.mp. 
273.burdenofskindisease.mp. 
274.patientreportedoutcomemeasure.mp. 
275.qualityoflifeimpairment.mp. 
276.outcomemeasurement.mp. 
277."OutcomeAssessment(HealthCare)"/oroutcomeassessment.mp. 
278.QOLtools.mp. 
279.patientreportedoutcome.mp. 
280.PRO.mp. 
281.NHP.mp. 
282.WHO-QOL.mp. 
283.psoriasisdisabilityindex.mp. 
284.PDI.mp. 
285.salfordpsoriasisindex.mp. 
286.SPI.mp. 
287.FDLQI.mp. 
288.PFI.mp. 
289.skindex-16.mp. 
290.skindex-29.mp. 
291.skindex-teen.mp. 
292.childrensdermatologylifequalityindex.mp. 
293.CDLQI.mp. 
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294.familydermatologylifequalityindex.mp. 
295.psoriasis-specificmeasureofqualityoflife.mp. 
296.PSORIQoL.mp. 
297.USPSORIQoL.mp. 
298.skindex-17.mp. 
299.DQOLS.mp. 
300.dermatologyqualityoflifescales.mp. 
301.shortform-36.mp. 
302.KMPI.mp. 
303.PDI.mp. 
304.nationalpsoriasisfoundationpsoriasisscore.mp. 
305.NPF-PS.mp. 
306.physicianstaticglobalassessment.mp. 
307.PSGA.mp. 
308.overalllesionassessment.mp. 
309.OLA.mp. 
310.physiciandynamicglobalassessment.mp. 
311.physiciandynamicglobalassessment.mp. 
312.PDGA.mp. 
313.latticesystemglobalpsoriasisscore.mp. 
314.LS-GPS.mp. 
315.PsAQoL.mp. 
316.dermatologyindexofdiseaseseverity.mp. 
317.DIDS.mp. 
318.psoriasislifestressinventory.mp. 
319.PLSI.mp. 
320.WHOQOL-26.mp. 
321.WHOQOL-100.mp. 
322.patientgeneralindex.mp. 
323.PGI.mp. 
324.DIELH.mp. 
325.VQ-dermato.mp. 
326.impactofchronicskindiseaseondailylife.mp. 
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327.ISDL.mp. 
328.freiberglifequalityassessment.mp. 
329.FLQA.mp. 
330.SF-29.mp. 
331.valueoflife/ 
332.qualityadjustedlifeyear/ 
333.qualityadjustedlife.tw. 
334.(qaly$orqald$orqale$orqtime$).tw. 
335.disabilityadjustedlife.tw. 
336.daly$.tw. 
337.healthstatusindicators/ 
338.(sf36orsf36orshortform36orshortform36orsfthirtysixorsfthirtysixorshortfo
rmthirtysixorshortformthirtysixorshortformthirtysixorshortformthirtysix).tw. 
339.(sf6orsf6orshortform6orshortform6orsfsixorsfsixorshortformsixorshortfor
msix).tw. 
340.(sf12orsf12orshortform12orshortform12orsftwelveorsftwelveorshortformt
welveorshortformtwelve).tw. 
341.(sf16orsf16orshortform16orshortform16orsfsixteenorsfsixteenorshortform
sixteenorshortformsixteen).tw. 
342.(sf20orsf20orshortform20orshortform20orsftwentyorsftwentyorshortform
twentyorshortformtwenty).tw. 
343.(euroqoloreuroqoloreq5doreq5d).tw. 
344.(hqlorhqolorhqolorhrqolorhrqol).tw. 
345.(hyeorhyes).tw. 
346.health$year$equivalent$.tw. 
347.healthutilit$.tw. 
348.(huiorhui1orhui2orhui3).tw. 
349.disutili$.tw. 
350.rosser.tw. 
351.qualityofwellbeing.tw. 
352.qwb.tw. 
353.willingnesstopay.tw. 
354.standardgamble$.tw. 
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355.timetradeoff.tw. 
356.timetradeoff.tw. 
357.tto.tw. 
358.or/264-357 
359.RandomizedControlledTrialsasTopic/ 
360.Randomi?edcontrolledtrial/ 
361.RandomAllocation/ 
362.DoubleBlindMethod/ 
363.SingleBlindMethod/ 
364.clinicaltrial/ 
365.clinicaltrial,phasei.pt. 
366.clinicaltrial,phaseii.pt. 
367.clinicaltrial,phaseiii.pt. 
368.clinicaltrial,phaseiv.pt. 
369.controlledclinicaltrial.pt. 
370.randomi?edcontrolledtrial.pt. 
371.multicenterstudy.pt. 
372.clinicaltrial.pt. 
373.expClinicalTrialsastopic/ 
374.randomly.ab. 
375.trial.ab. 
376.groups.ab. 
377.or/359-376 
378.(clinicaladjtrial$).tw. 
379.((singl$ordoubl$ortreb$ortripl$)adj(blind$3ormask$3)).tw. 
380.PLACEBOS/ 
381.placebo$.tw. 
382.randomlyallocated.tw. 
383.(allocatedadj2random$).tw. 
384.or/378-383 
385.377or384 
386.casereport.tw. 
387.letter/ 
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388.historicalarticle/ 
389.or/386-388 
390.385not389 
391.15and263and358and390 
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